- Home
- ACRE vs TARA Comparison
ACRE vs TARA Comparison
Compare ACRE & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRE | TARA |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.1M | 268.5M |
| IPO Year | 2011 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ACRE | TARA |
|---|---|---|
| Price | $5.35 | $5.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $5.38 | ★ $23.60 |
| AVG Volume (30 Days) | 395.8K | ★ 581.5K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 11.15% | N/A |
| EPS Growth | 26.17 | ★ 38.25 |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $54,833,000.00 | $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.28 | N/A |
| P/E Ratio | $3.97 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.71 | $2.77 |
| 52 Week High | $5.89 | $7.82 |
Technical Indicators
Market Signals| Indicator | ACRE | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 66.33 | 49.62 |
| Support Level | $4.66 | $4.92 |
| Resistance Level | $5.55 | $5.44 |
| Average True Range (ATR) | 0.12 | 0.26 |
| MACD | 0.06 | 0.06 |
| Stochastic Oscillator | 98.64 | 69.26 |
Price Performance
Historical ComparisonAbout ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).